查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球孤兒藥市場 2023-2030
市場調查報告書
商品編碼
1380385

全球孤兒藥市場 2023-2030

Global Orphan Drugs Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 210 Pages | 商品交期: 2-3個工作天內

價格

全球孤兒藥市場預計在預測期內（2023-2030年）CAGR為11.8%。市場的成長歸因於全球孤兒藥的重要性和目的。孤兒藥是為治療特定罕見疾病而開發的藥理化合物。極少數患者通常患有上述罕見疾病。由於患者基數較小，如果沒有政府的援助和激勵，這些藥物的開發在經濟上可能不可行。根據 BMJ 報導，2023 年 5 月，一種被稱為孤兒藥的藥物被開發用於治療特定的罕見疾病。除了患有這些疾病的患者數量極少之外，如果沒有政府的援助，孤兒藥的開發也無法在商業上可行。孤兒藥預計將佔全球所有處方藥銷售額（不包括學名藥）的 20%，年市場成長率為 11.7%，而非孤兒藥為 5.9%。然而，隨著遺傳學和精準醫學的發展，使用越來越有限的疾病術語來為越來越多的藥物提供孤兒地位，引起了人們的擔憂。此外，由於癌症在全球的流行，每年報告有 1400 萬新病例和 800 萬人死於癌症。對創新和有效的癌症治療的需求正在迅速成長，據估計，到 2040 年，病例數可能會增加到 2,200 萬。最終，由於消費者基礎有限，罕見癌症的治療有時很難獲得所需的資金。

細分市場前景

全球孤兒藥市場按藥物類型、疾病類型和配銷通路進行細分。根據疾病類型，市場分為生物和非生物。根據疾病類型，市場細分為腫瘤學、血液學、神經學、心血管學等。此外，根據配銷通路，市場分為醫院藥房、零售藥房、網路藥房等。腫瘤學子類別預計將佔據疾病類型細分市場的很大一部分市場佔有率。這歸因於腫瘤疾病盛行率的增加、癌症意識的提高、早期癌症篩檢以及用於癌症治療的腫瘤孤兒藥物的可用性。

預計心血管細分市場將在全球孤兒藥市場中佔據相當大的佔有率

在疾病類型中，心血管細分市場預計將在全球孤兒藥市場中佔據相當大的佔有率。細分市場的成長歸因於對心血管健康的考慮。鈉攝取量增加與多種心血管危險因素，特別是高血壓（高血壓）直接相關。有趣的是，XywavTM 的鈉含量較低，這與攝取過量鈉相關的更廣泛的健康問題不謀而合。例如，2021年6月，Jazz Pharmaceuticals plc推出了XywavTM（鈣、鎂、鉀和鈉羥丁酸鹽）口服溶液，用於治療7歲及以上發作性睡病患者的猝倒或日間過度嗜睡（ EDS）。美國食品藥物管理局 (FDA) 已授予七年孤兒藥獨佔權。 Xywav（一種羥丁酸鹽產品）的鈉含量比建議劑量範圍為 6 至 9 克（或約 1,000 至 1,500 毫克/晚）的羥丁酸鈉低 92%。

區域展望

全球孤兒藥市場根據地理位置進一步細分，包括北美（美國和加拿大）、歐洲（英國、義大利、西班牙、德國、法國和歐洲其他地區）、亞太地區（印度、中國、日本） 、韓國和亞洲其他地區）以及世界其他地區（中東和非洲以及拉丁美洲）。其中，由於政府增加社區健康和腫瘤中心數量的舉措，預計亞太地區將在全球市場中佔據顯著佔有率，預計將擴大新興國家的孤兒藥市場。

預計歐洲地區全球孤兒藥市場將以顯著的複合CAGR成長

在所有地區中，歐洲地區預計在預測期內將以相當大的CAGR成長。區域成長歸因於該地區罕見疾病範圍的廣泛增加。迄今為止已發現的 7000 多種罕見疾病中，大多數都有遺傳基礎。由於其中幾種疾病被認為是有害的，因此有效治療的緊迫性越來越大。根據 Pharmaceutical Technology 報告，截至 2022 年 7 月，據信目前存在 7,000 多種罕見疾病，其中大多數是遺傳性的，其中許多被認為危及生命。根據歐盟的定義，孤兒病儘管患病率很高，但約有 2,000 人患有此病。

市場參與者展望

服務於孤兒藥市場的主要公司包括：阿斯特捷利康(AstraZeneca)、羅氏(F. Hoffmann-La Roche Ltd)、拜耳(Bayer)、百時美施貴寶印度私人有限公司(Bristol-Myers Squibb India Pvt.) 。株式會社、第一三共株式會社等。市場參與者透過各種策略（包括併購、合作、合作、融資和新產品發布），為市場成長做出了巨大貢獻，以保持市場競爭力。例如，2021 年 11 月，Emmes 推出了新中心 Orphan Reach，作為獨特的「稀有 CRO」。該公司以精通公共部門和生物製藥行業的公共衛生研究而聞名，並已被涵蓋新的罕見疾病中心。

報告涵蓋：

  • 2022年市場價​​值資料分析及2030年預測。
  • 每個細分市場的年化市場收入（百萬美元）。
  • 主要地理區域的國家分析。
  • 在全球孤兒藥市場營運的主要公司。根據現有資料，報告中還提供了與新產品發布相關的資訊以及相關新聞。
  • 透過確定未來強勁成長的關鍵細分市場來分析業務策略。
  • 市場進入和市場擴張策略分析。
  • 透過識別市場中「誰的立場」來制定競爭策略。

目錄

第 1 章：報告摘要

  • 目前行業分析及成長潛力展望
  • 研究方法和工具
  • 市場區隔
    • 按細分
    • 按地區

第 2 章：市場概述與見解

  • 報告範圍
  • 分析師見解和當前市場趨勢
    • 主要發現
    • 建議
    • 結論

第 3 章：競爭格局

  • 主要公司分析
  • AbbVie Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Alexion Pharmaceuticals, Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Amgen Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • 關鍵策略分析

第 4 章：市場細分

  • 按藥物類型分類的全球孤兒藥市場
    • 生物
    • 非生物的
  • 按疾病類型分類的全球孤兒藥市場
    • 腫瘤學
    • 血液學
    • 神經病學
    • 心血管
    • 其他（自體免疫疾病和罕見血液疾病）
  • 按配銷通路分類的全球孤兒藥市場
    • 醫院藥房
    • 零售藥房
    • 網路藥房
    • 其他（專業藥房和直接面向患者的分銷）

第 5 章：區域分析

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 歐洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 世界其他地區

第 6 章：公司簡介

  • AstraZeneca.
  • At F. Hoffmann-La Roche Ltd
  • Bayer AG
  • Bristol-Myers Squibb India Pvt. Ltd.
  • Daiichi Sankyo Co. Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson Pvt. Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.
Product Code: OMR2027794

Title: Global Orphan Drugs Market Size, Share & Trends Analysis Report by Drug Type (Biological, and Non-biological), by Disease Type (Oncology, Hematology, Neurology, Cardiovascular, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others),Forecast Period (2023-2030).

The global orphan drugs market is anticipated to grow at a CAGR of 11.8% during the Forecast Period (2023-2030). The market's growth is attributed to significance and purpose of orphan drugs across the globe. Orphan pharmaceuticals are pharmacological compounds developed to treat particular rare medical conditions. A minimal number of patients normally suffer the aforementioned rare disorders. These medications can be financially unviable to develop without government assistance and incentives owing to their small patient bases. According to the BMJ, in May 2023, a pharmacological agent referred to as an orphan drug that has been developed to treat specific rare medical diseases. In addition to the tiny number of patients with the diseases, an orphan medicine cannot be made commercially viable to develop without government aid. Orphan medications are projected to account for 20% of all prescription drug sales globally (excluding generics), with an annual market growth rate of 11.7% vs 5.9% for non-orphan drugs. The use of increasingly limited disease terms to provide orphan status to a growing number of medications, rendered accessible by developments in genetics and precision medicine, raised concerns, though. Furthermore, 14 million new cases and 8 million fatalities from cancer are reported annually owing to its global prevalence. The demand for innovative and potent cancer treatments is increasing rapidly as estimates indicate that the number of cases can rise to 22 million by the year 2040. Ultimately, owing to their limited consumer base, treatments for uncommon cancers sometimes struggle to acquire the funding they demand.

Segmental Outlook

The global orphan drugs market is segmented on the drug type, disease type, and distribution channel. Based on the disease type, the market is sub-segmented into biological, and non-biological. Based on the disease type, the market is sub-segmented into oncology, hematology, neurology, cardiovascular, and others. Furthermore, on the basis of distribution channel, the market is sub-segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others. The oncology subcategory is expected to capture a significant portion of the market share within the disease type segment. This is attributed to the increase in the prevalence of oncological diseases, increased awareness of cancer, early cancer screening, and the availability of oncological orphan medications for cancer treatment.

The Cardiovascular Sub-Segment is Anticipated to Hold a Considerable Share of the Global Orphan Drugs Market

Among the disease type, the cardiovascular sub-segment is expected to hold a considerable share of the global orphan drugs market. The segmental growth is attributed to the considerations for cardiovascular health. Increased sodium consumption has a direct correlation with several cardiovascular risk factors, particularly hypertension (high blood pressure). It is interesting that XywavTM has less sodium that coincides with broader health concerns related to consuming excessive sodium. For instance, in June 2021, Jazz Pharmaceuticals plc, launched the XywavTM (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. The U.S. Food and Drug Administration (FDA) has recognized seven years of Orphan Drug Exclusivity. The sodium content of Xywav, an oxybate product, is 92% lower than that of sodium oxybate in the recommended dosage range of 6 to 9 grams, or roughly 1,000 to 1,500 mg/night.

Regional Outlook

The global orphan drugs market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to the increased government initiatives to boost the number of community health and oncology centers are anticipated to expand the market for orphan medications in emerging nations.

The Europe Region is Expected to Grow at a Significant CAGR in the Global Orphan Drugs Market

Among all regions, the Europe regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the rising wide range of orphan diseases across the region. The majority of the more than 7,000 orphan diseases that have been identified so far have genetic bases. There is an increased urgency for effective treatments owing to several of these diseases are thought to be harmful. According to Pharmaceutical Technology, in July 2022, More than 7,000 orphan diseases are believed to exist at the moment, the majority of that are genetic in origin and many of that are regarded as life-threatening. Orphan diseases, as defined by the European Union, afflict approximately in 2,000 individuals, despite their significant prevalence.

Market Players Outlook

The major companies serving the orphan drugs market include: AstraZeneca., At F. Hoffmann-La Roche Ltd, Bayer AG, Bristol-Myers Squibb India Pvt. Ltd., Daiichi Sankyo Co. Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance in November 2021, Emmes launched its new center, Orphan Reach as a unique 'rare CRO'. The company renowned for proficiency in public health research across the public sector and biopharmaceutical industry has been included into the new rare diseases center.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global orphan drugs market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. AbbVie Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Alexion Pharmaceuticals, Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Amgen Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Orphan Drugs Market by Drug Type
    • 4.1.1. Biological
    • 4.1.2. Non-biological
  • 4.2. Global Orphan Drugs Market by Disease Type
    • 4.2.1. Oncology
    • 4.2.2. Hematology
    • 4.2.3. Neurology
    • 4.2.4. Cardiovascular
    • 4.2.5. Others (Autoimmune Diseases, and Rare Blood Disorders)
  • 4.3. Global Orphan Drugs Market by Distribution Channel
    • 4.3.1. Hospital Pharmacy
    • 4.3.2. Retail Pharmacy
    • 4.3.3. Online Pharmacy
    • 4.3.4. Others (Specialty Pharmacies, and Direct-to-Patient Distribution)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. AstraZeneca.
  • 6.2. At F. Hoffmann-La Roche Ltd
  • 6.3. Bayer AG
  • 6.4. Bristol-Myers Squibb India Pvt. Ltd.
  • 6.5. Daiichi Sankyo Co. Ltd.
  • 6.6. GlaxoSmithKline plc
  • 6.7. Johnson & Johnson Pvt. Ltd.
  • 6.8. Novartis AG
  • 6.9. Pfizer Inc.
  • 6.10. Sanofi
  • 6.11. Takeda Pharmaceutical Co. Ltd.

LIST OF TABLES

  • 1. GLOBAL ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL BIOLOGICAL ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL NON-BIOLOGICAL ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2022-2030 ($ MILLION)
  • 5. GLOBAL ORPHAN DRUGS IN ONCOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL ORPHAN DRUGS IN HEMATOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL ORPHAN DRUGS IN NEUROLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL ORPHAN DRUGS IN CARDIOVASCULAR MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL ORPHAN DRUGS IN OTHER DISEASE TYPES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 11. GLOBAL ORPHAN DRUGS BY HOSPITAL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL ORPHAN DRUGS BY RETAIL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL ORPHAN DRUGS BY ONLINE PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL ORPHAN DRUGS BY OTHER DISTRIBUTION CHANNELS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. GLOBAL ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. NORTH AMERICAN ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2022-2030 ($ MILLION)
  • 19. NORTH AMERICAN ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 20. EUROPEAN ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 21. EUROPEAN ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 22. EUROPEAN ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE , 2022-2030 ($ MILLION)
  • 23. EUROPEAN ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 24. ASIA- PACIFIC ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 25. ASIA- PACIFIC ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 26. ASIA- PACIFIC ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2022-2030 ($ MILLION)
  • 27. ASIA- PACIFIC ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL , 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL ORPHAN DRUGS MARKET SHAREBY DRUG TYPE, 2022 VS 2030 (%)
  • 2. GLOBAL BIOLOGICAL ORPHAN DRUGS MARKET SHAREBY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL NON-BIOLOGICAL ORPHAN DRUGS MARKET SHAREBY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL ORPHAN DRUGS MARKET SHAREBY DISEASE TYPE, 2022 VS 2030 (%)
  • 5. GLOBAL ORPHAN DRUGS IN ONCOLOGY MARKET SHAREBY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL ORPHAN DRUGS IN HEMATOLOGY MARKET SHAREBY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL ORPHAN DRUGS IN NEUROLOGY MARKET SHAREBY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL ORPHAN DRUGS IN CARDIOVASCULAR MARKET SHAREBY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL ORPHAN DRUGS IN OTHER DISEASE TYPES MARKET SHAREBY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL ORPHAN DRUGS MARKET SHAREBY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
  • 11. GLOBAL ORPHAN DRUGS BY HOSPITAL PHARMACY MARKET SHAREBY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL ORPHAN DRUGS BY RETAIL PHARMACY MARKET SHAREBY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL ORPHAN DRUGS BY ONLINE PHARMACY MARKET SHAREBY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL ORPHAN DRUGS FOR OTHER DISTRIBUTION CHANNELS MARKET SHAREBY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL ORPHAN DRUGS MARKET SHAREBY REGION, 2022 VS 2030 (%)
  • 16. US ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. CANADA ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. UK ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. FRANCE ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. GERMANY ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. ITALY ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. SPAIN ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. REST OF EUROPE ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. INDIA ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. CHINA ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. JAPAN ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. REST OF ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)